Scientific & Research Department, Velleja Research, Milano, Italy.
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Pathol Oncol Res. 2023 Aug 2;29:1611300. doi: 10.3389/pore.2023.1611300. eCollection 2023.
Recent studies have highlighted a possible correlation between microbiota composition and the pathogenesis of various oncological diseases. Also, many bacterial groups are now directly or indirectly associated with the capability of stimulating or inhibiting carcinogenic pathways. However, little is known about the importance and impact of microbiota patterns related to the efficacy and toxicity of cancer treatments. We have recently begun to understand how oncological therapies and the microbiota are closely interconnected and could influence each other. Chemotherapy effectiveness, for example, appears to be strongly influenced by the presence of some microorganisms capable of modulating the pharmacokinetics and pharmacodynamics of the compounds used, thus varying the real response and therefore the efficacy of the oncological treatment. Similarly, chemotherapeutic agents can modulate the microbiota with variations that could facilitate or avoid the onset of important side effects. This finding has or could have considerable relevance as it is possible that our ability to modulate and modify the microbial structure before, during, and after treatment could influence all the clinical parameters related to pharmacological treatments and, eventually, the prognosis of the disease.
最近的研究强调了微生物群落组成与各种肿瘤疾病发病机制之间可能存在的相关性。此外,许多细菌群现在直接或间接地与刺激或抑制致癌途径的能力有关。然而,关于与癌症治疗的疗效和毒性相关的微生物群模式的重要性和影响知之甚少。我们最近开始了解肿瘤治疗和微生物群是如何紧密相关并相互影响的。例如,化疗的有效性似乎受到某些能够调节所用化合物药代动力学和药效学的微生物存在的强烈影响,从而改变了真正的反应,因此也改变了肿瘤治疗的疗效。同样,化疗药物可以调节微生物群,这些变化可能会促进或避免重要副作用的发生。这一发现具有或可能具有相当大的意义,因为在治疗前后,我们有可能调节和改变微生物结构,这可能会影响与药物治疗相关的所有临床参数,并最终影响疾病的预后。